Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Orlistat
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Sponsor : CTC Clinical Trial Consultants
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase 1 Study to Evaluate EMP22 PD and EMP16 PK Versus Xenical® in Healthy Volunteers
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 28, 2023
Lead Product(s) : Orlistat
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Sponsor : CTC Clinical Trial Consultants
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Orlistat
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : CTC Clinical Trial Consultants
Deal Size : Inapplicable
Deal Type : Inapplicable
Study Exploring the Supportive Effect of Acarbose in Weight Management
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 06, 2023
Lead Product(s) : Orlistat
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : CTC Clinical Trial Consultants
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Orlistat
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacodynamic Equivalence Study Of Orlistat Capsules 60 mg
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 13, 2021
Lead Product(s) : Orlistat
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Orlistat
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I/ Phase II
Sponsor : CTC Clinical Trial Consultants
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 21, 2020
Lead Product(s) : Orlistat
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I/ Phase II
Sponsor : CTC Clinical Trial Consultants
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Orlistat
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 10, 2019
Lead Product(s) : Orlistat
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Orlistat
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Phase IV
Sponsor : Healthway Pharmacy | Michigan Public Health Departments | National Institute of Environmental Health Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Weight Loss Aid in an Exposed Population
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 11, 2018
Lead Product(s) : Orlistat
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Phase IV
Sponsor : Healthway Pharmacy | Michigan Public Health Departments | National Institute of Environmental Health Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Orlistat
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 11, 2016
Lead Product(s) : Orlistat
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Orlistat
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
RCT to Compare Orlistat and Polyglucosamine for the Management of Overweight and Obesity
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 20, 2015
Lead Product(s) : Orlistat
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Orlistat
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Undisclosed
Sponsor : Hamell
Deal Size : Inapplicable
Deal Type : Inapplicable
Risk Management Plan (RMP) Survey for Purchasers of Alli® (60 mg Orlistat) in the European Union.
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 19, 2014
Lead Product(s) : Orlistat
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Undisclosed
Sponsor : Hamell
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Orlistat
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 24, 2014
Lead Product(s) : Orlistat
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable